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Background: Even though an inflammatory process is known to be the underlying cause of
asthma, diagnosis is based on clinical history, reversible airway obstruction and bronchial
hyperresponsiveness according to international guidelines. The fraction of exhaled nitric
oxide (FENO) and induced sputum eosinophil count (Eos%) have been used as non-invasive
inflammatory biomarkers.
Objectives: The aim of this study was to compare the sensitivity and specificity of FENO,
Eos% and spirometry and to assess whether their combined use in clinical practice would
improve diagnostic yield.
Methods: In 50 patients with asthma symptoms we performed spirometry, a methacholine
challenge test, FENO measurement and assessment of Eos% in induced sputum. The
standard diagnosis of asthma followed the guidelines of the Global Initiative for Asthma.
Results: Twenty-two of the 50 patients were diagnosed with asthma. The sensitivity and
diagnostic accuracy were higher for FENO measurement (77%; area under the receiver
operating curve [AUC], 0.8) than for spirometry (22%; AUC, 0.63). The sensitivity and
specificity of Eos% in induced sputum were 40% and 82%, respectively, and the diagnostic
accuracy of Eos% was lower (AUC, 0.58). When both inflammatory biomarkers were used
together specificity increased to 76%.
Conclusions: The diagnostic accuracy of FENO measurement was superior to that of the
standard diagnostic spirometry in patients with symptoms suggestive of asthma. The use ofPublished by Elsevier Ltd.
led nitric oxide; Eos%, eosinophil count expressed as a percentage; PPV, positive predictive value; NPV,
ed expiratory volume in 1 s; FVC, forced vital capacity; ppb, parts per billion; PD20, the dose of
in FEV1; ROC, receiver operating characteristic curve; AUC, area under the receiver operating
5565972; fax: +34 93 5565601.
es (A.Ma. Fortuna).
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Diagnostic utility of inflammatory biomarkers in asthma 2417FENO measurement and induced sputum Eos% together to diagnose asthma in clinical
practice is more accurate than spirometry or FENO assessment alone and easier to perform.
& 2007 Published by Elsevier Ltd.Introduction
Asthma is a chronic airway disease whose diagnosis is based
on clinical history, reversible airway obstruction and
bronchial hyperresponsiveness.1 However, the real cause of
these functional disorders is a chronic inflammatory process
in which mastocytes and eosinophils play a major role.2
Because conventional approaches to diagnosing asthma do
not involve an assessment of airway inflammation, the
fraction of exhaled nitric oxide (FENO) and the induced
sputum eosinophil count expressed as a percentage (Eos%)
have been proposed as inflammatory biomarkers that are
useful in this setting.3,4 Several studies have demonstrated
that each of these biomarkers is more accurate than
standard approaches to the diagnosis of asthma,5,6 but the
accuracy of both used together has not been assessed. We
therefore hypothesised that diagnostic yield in terms of
specificity and sensitivity might improve if both tests were
used together.
Our aim was to analyse the sensitivity, specificity and
positive and negative predictive values of FENO measure-
ment and Eos% in comparison with conventional diagnostic
tests (spirometry, bronchodilator response and methacho-
line challenge) in the diagnosis of asthma. We also sought to
evaluate whether using both inflammatory biomarkers
together would provide greater diagnostic accuracy in
patients with a clinical history suggestive of asthma.
Material and methods
Patients
Fifty-seven consecutive patients were recruited for pro-
spective study. All were referred to our hospital-based
respiratory medicine outpatient clinic for diagnosis with a
clinical history suggestive of asthma (dry cough, wheezing,
and shortness of breath) from October 2004 to November
2005. We excluded patients with conditions that could
affect FENO or Eos% measurement for reasons other than
asthma: subjects with symptoms of respiratory tract
infection in the previous 6 weeks or with systemic
manifestations of atopy (rash, digestive symptoms, etc.)
and patients who had received treatment with inhaled or
oral corticosteroids in the last 4 weeks. All patients enrolled
agreed to participate voluntarily and gave written informed
consent. The institutional review board of our hospital
approved the study.
Study design
The tests in this prospective study were conducted on 2
consecutive days. The first day the patient filled in a clinical
symptoms questionnaire7 and underwent FENO measure-
ment, spirometry with bronchodilator response and collec-tion of induced sputum. The next day a methacholine
challenge test was performed. All the procedures were
carried out at the same hour of each day and in an order that
guaranteed that the results of one test did not interfere
with the next. Trained members of our lung function
laboratory staff executed the tests.
Study procedures
The tests of reference for the diagnosis of asthma were the
conventional lung function tests (spirometry and broncho-
dilator response) and methacholine challenge test following
guidelines of the Global Initiative for Asthma (GINA).1
Spirometry was performed following international guide-
lines8 with a Datospir 120 (Sibelmed, Barcelona, Spain). A
forced expiratory volume in 1 s (FEV1)X80% of predicted
and/or a ratio of FEV1 to forced vital capacity (FVC)X75%
were considered to lie within normal limits.
Spirometry results lying outside the reference limits were
classified as mild obstruction (60%pFEV1X74%), moderate
(59%pFEV1X40%), or severe (FEV1p39%). A positive
bronchodilator response was defined as an increase in
FEV1X15% and/or X200mL from baseline after inhalation
of 400 mg of salbutamol.8
The methacholine challenge was performed according to
international guidelines as a dose–response test of increas-
ing doses of methacholine chlorohydrate (0.1–32mg/mL)
every 5min.9 The test was stopped when the highest
concentration (32mg/mL) was tolerated, or if a fall of 20%
in FEV1 from baseline was induced after methacholine was
inhaled. The results were expressed as the dose of
methacholine provoking a 20% fall in FEV1 (PD20). A
methacholine challenge test was considered positive if the
PD20 was p16mg/mL.9 A subject who presented a clinical
history suggestive of asthma and a positive methacholine
challenge test was diagnosed with asthma following the
GINA guidelines.1
Inflammatory biomarkers
FENO measurement was performed with a conventional
chemoluminescence analyser (SIR N-6008, Madrid, Spain)
according to international guidelines.10,11 The standardised
single breath technique was used; each patient inhaled to
total lung capacity once and then exhaled at a constant flow
rate of 50mL/s for approximately 10 s. A resistance with a
pressure above 5–20 cm H2O was provided to ensure velum
closure and to exclude contamination from nasal NO. To
interpret FENO recordings, we took only the valid NO plateau
of the exhalation curve (held for43 s and with a variation of
o10%). The mean value of FENO from three technically valid
measurements was recorded. The cutoff for a positive result
was defined as a FENOX20 parts per billion (ppb).
12
Sputum induction was carried out following described
procedures.13 Briefly, each patient gave a sputum sample
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Table 1 Characteristics of patients.
Characteristics Non-asthmatic
patients
Asthmatic
patients
Patients (no.) 28 22
Age (year), mean
(range)
38 (18–64) 37 (18–68)
Gender (no.)
Male 10 11
Female 18 11
FEV1 (%)
(mean7SD)
99710 94719
FVC (%) 101710 104717
A.Ma. Fortuna et al.2418induced with hypertonic saline. Sputum was separated from
saliva to avoid inclusion of squamous cells, and the total
nonsquamous cell count was performed. Cell viability was
determined by the trypan blue exclusion method. The
filtrate was treated within 2 h with a solution of dithio-
threitol and then centrifuged. The sediment was stained
with Papanicolaou stain, toluidine blue and eosin hematox-
ylin. The differential cell count, including metachromatic
cells, was expressed as the absolute number of cells in
millions per gram of sputum and as the percentage of the
total nonsquamous and bronchial epithelial cells. An
adequate sputum sample was assumed if induction was
tolerated for at least 4min, the volume was 41mL and
squamous cell percentage was o20%.14 The cutoff for a
positive Eos% result was defined as X3%.14(mean7SD)
FEV1/FVC (%)
(mean7SD)
7876.3 73712
FENO (ppb)
(mean7SD)
18723 40731
Eos%, induced
sputum
(mean7SD)
2.173.3 4.578.5
Bronchodilator
test no. (%)
Positive: 4 (14.3) Positive: 9
(40.9%)
Negative: 24
(85.7)
Negative: 13
(59.1%)
Smokers patients
(no.)
4 smokers; 3 ex-
smokers
3 smokers; 4 ex-
smokers
Statistically significant, po0.05.
Nonstatistically significant, p40.05.Statistical analysis
Descriptive statistics were expressed as mean7SD. The
comparisons of anthropometric and other variables between
groups were performed using the Mann–Whitney U-test.
Diagnostic accuracy was assessed based on the area under
the receiver operating characteristic curve (AUC). The
Pearson correlation coefficient was used to assess the
relationship between PD20 and each of the two inflammatory
biomarkers. Forward binary logistic regression was used to
estimate the added usefulness of assessing both Eos% in
induced sputum along with FENO. Relevant odds ratios and
the 95% confidence intervals (CI) were calculated. A p-value
o0.05 was considered statistically significant. An indepen-
dent statistician analysed the raw data. The SPSS version
11.5 statistical package (Chicago, Illinois, USA) was used for
all analyses.Results
Of 57 patients with a clinical history suggestive of asthma
recruited, 7 were excluded because they were receiving oral
corticosteroid treatment at the time of the study. Table 1
shows the clinical characteristics of the remaining 50
patients. The methacholine airway challenge test was
positive in 22 patients and they were diagnosed with
asthma. The diagnoses of the remaining 28 patients were
eosinophilic bronchitis (5 patients, 17%), chronic rhinitis (14,
50%), chronic cough (6, 21%) and acute bronchitis (3, 10%).
No adverse events occurred during performance of the
procedures. All patients were able to produce sputum and
perform the FENO procedure. Our induced sputum samples
were minimally contaminated with saliva (mean squamous
cell count of 6% and viability cellular of 64.
The FEV1 and FEV1/FVC values were within reference
limits for 45 patients (90%) and 5 patients presented airflow
obstruction (4, moderate; 1, severe). There were no
significant differences in age, sex, body mass index, FEV1,
or FEV1/FVC between patients diagnosed with asthma and
patients with other diagnoses.
The mean FENO value was significantly higher in asth-
matics at 40731 ppb than in non-asthmatic patients
(18723 ppb) (p ¼ 0.04). The mean Eos% in induced sputum
tended to be higher in asthmatics (4.578.5%) than in non-asthmatic patients (2.173.3%) but the difference was not
statistically significant (p ¼ 0.07).
Table 2 shows the sensitivity, specificity and positive and
negative predictive values of the diagnostic procedures.
FENO measurement was the procedure that presented the
highest sensitivity (77%). The figures show the receiver
operating characteristic curves for the lung function vari-
ables (Fig. 1), FENO and Eos% in induced sputum (Fig. 2) and
the combined use of both inflammatory biomarkers (Fig. 3).
The highest accuracy (sensitivity and specificity combined)
was achieved by FENO measurement, with a mean AUC of
0.80 (95% CI, 0.62–0.87; po0.001). The cutoff that best
distinguished between asthmatics and non-asthmatics was a
FENO value of 23 ppb.
The AUC for Eos% in induced sputum was 0.56 (95% CI,
0.41–0.70; po0.001) at an Eos% cutoff of 4%. Spirometry
presented an AUC of 0.64 (95% CI, 0.49–0.77; po0.008) for
FEV1 and 0.63 (95% CI, 0.48–0.76; po0.006) for FEV1/FVC.
A significant negative correlation between FENO and PD20
was observed (r ¼ 0.4; p ¼ 0.004). Forward logistic
regression showed that the addition of sputum Eos% to FENO
measurement improved the diagnostic accuracy by increas-
ing the specificity (specificity of FENO plus induced sputum,
76%, po0.05 vs. 64% specificity for FENO alone). The
addition of the standard diagnostic procedures (lung
function tests and bronchodilator test) to FENO measure-
ment did not increase accuracy.
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Table 2 Sensitivity, specificity and positive and negative predictive values of FENO, Eos% in induced sputum and spirometry in
the diagnosis of asthma.
Patients asthmatics
(n ¼ 22)
Patients no
asthmatics (n ¼ 28)
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
FENO

Positive 17 10 77 64 62 78
Negative 5 18
Induced sputum (Eos%)y
Positive 9 7 41 75 56 61
Negative 13 21
FEV1
o80% 5 0 22 100 100 56
X80% 17 22
Bronchodilator testz
Positive 9 4 41 85 69 64
Negative 13 24
FENO positive: X20 ppb; negative: p19 ppb.
yInduced sputum (Eos%) positive: X3%; negative: p2.9%.
zBronchodilator test positive is the increase in FEV1X15% and/or X200mL from baseline after inhalation of 400mg of salbutamol.
Figure 1 Receiver operating characteristic curve (ROC) for
forced expiratory volume in 1 s (FEV1, solid line) and the ratio of
FEV1 to forced vital capacity ratio (FVC, dotted line).
Figure 2 Receiver operating characteristic curve for the
exhaled nitric oxide measurement (FENO, solid line) and Eos%
in induced sputum (dotted line). The FENO measurement shows
higher area under the receiver operating characteristic curve
(AUC) than Eos% in induced sputum.
Diagnostic utility of inflammatory biomarkers in asthma 2419The correlation between Eos% in induced sputum and PD20
was not statistically significant (r ¼ 0.2; p ¼ 0.4), and
adding Eos% measurement to the standard diagnostic
procedures (lung function tests) produced no statistically
significant increase in diagnostic accuracy.Discussion
In this study, we have confirmed that measurement of FENO
as an inflammatory biomarker and in patients with highclinical suspicion of asthma it offers higher diagnostic
sensitivity than the standard approach based on lung
function and methacholine challenge testing, and we have
further shown that using measurement of both FENO and
induced sputum Eos% together increased the accuracy of
diagnosis.
Conventional procedures for diagnosing asthma according
to international guidelines require the demonstration of
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Figure 3 Receiver operating characteristic curve for the
exhaled nitric oxide measurement (FENO) plus Eos% in induced
sputum.
A.Ma. Fortuna et al.2420airway obstruction and/or bronchial hyperresponsiveness.1
These procedures distinguish healthy individuals from
patients according to the type and degree of airway
obstruction, even though findings vary greatly because of
individual airway variability and differing degrees of patient
cooperation. Of 22 patients diagnosed with asthma based on
a positive methacholine challenge test in our study, only 5
patients presented airflow obstruction by spirometry. The
remaining 17 asthmatic patients presented normal FEV1 and
FEV1/FVC values and FENO values 420 ppb, indicating a
diagnosis of asthma by inflammatory biomarker but not by
spirometry. These findings support a conclusion that this
biomarker offers a useful tool for diagnosing asthma in
patients who present spirometry values within the normal
reference limits. The high significant correlation between
FENO and PD20 also supports the use of FENO assessment to
obtain a more accurate diagnosis of asthma, with less
variability than with standard procedures. Moreover FENO is
an easier technique to use in patients with mild asthma and
it is safer in patients with severe airway obstruction (FEV1
o50%). The negative predictive value of FENO measurement
is very acceptable and greater than that of spirometry or
induced sputum Eos% assessment. Thus, FENO measurement
can rule out an inflammatory respiratory process in 78% of
the patients, giving it considerable diagnostic capability.
The cutoff for FENO measurement that shows the best
combination of sensitivity and specificity in the diagnosis of
asthma in our study was 23 ppb, consistent with the cutoff
established in the literature.5,10,15 The lower sensitivity of
induced sputum Eos% in comparison with the sensitivity of
FENO measurement is attributable to the periodic character
of sputum eosinophil increases in some asthmatic patients.16
The higher specificity of Eos% (77%) in comparison with FENO
(64%) supports of a diagnostic role for induced sputum Eos%
measurement in eosinophilic diseases with asthmatic symp-toms, such as eosinophilic bronchitis, occupational asthma
and chronic cough. On the other hand, there are various
airway inflammatory diseases—such as chronic obstructive
pulmonary disease,17 bronchiectasis,18 or lung cancer19—
where NO levels are elevated. Our findings also encourage
the addition of induced sputum Eos% to FENO measurement
to increase diagnostic yield in these cases. Thus, when we
used both biomarkers together, the forward logistic regres-
sion model showed higher specificity in the diagnosis of
patients with a clinical history suggestive of asthma. This
improvement in specificity is not observed when spirometry
and methacholine challenge test results are added to FENO
assessment.
This study has confirmed the utility of FENO for diagnosing
asthma in populations with clinical symptoms suggestive of
the disease. FENO measurement led to a faster, more
convenient and more accurate diagnosis of asthma than
standard procedures. Additionally, we found that using both
FENO and induced sputum Eos% together to diagnose asthma
is more accurate than spirometry or FENO assessment alone
and easier to perform than methacholine challenge test.
These non-invasive techniques to measure inflammatory
biomarkers offer simple, complementary and reproducible
diagnostic tools for diagnosing asthma in clinical practice,
suggesting an approach that may lead to a new definition of
asthma in the future.
Acknowledgments
M.E. Kerans provided assistance with English usage in a
version of the manuscript.
None of the authors of this manuscript have a conflict of
interest to declare in relation to this work.
References
1. Global Initiative for Asthma. Global strategy for Asthma
Management and Prevention NHLBI/WHO workshop report. No.
02-3659, 2002.
2. Barnes PJ. Pathophysiology of asthma. Eur Respir J 2003;23:
84–113.
3. Jatakanon A, Sim L, Kharitonov SA, Chung KF, Barnes PJ.
Correlation between exhaled nitric oxide, sputum eosinophils,
and methacholine responsiveness in patients with mild asthma.
Thorax 1998;53:91–5.
4. Strunk RC, Szefler SJ, Phillips B, et al. Relationship of exhaled
nitric oxide to clinical and inflammatory markers of persistent
asthma in children. Am Acad Allergy Asthma Immunol
2003;112:883–92.
5. Smith AD, Cowan JO, Filsell S, et al. Comparisons between
exhaled nitric oxide measurements and conventional tests. Am
J Respir Crit Care Med 2004;169:473–8.
6. Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation
of the validity of exhaled nitric oxide for the diagnosis of
asthma. Chest 2003;123:751–6.
7. Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR.
Development and validation of a questionnaire to measure
asthma control. Eur Respir J 1999;14:902–7.
8. American Thoracic Society. Standardization of spirometry. Am
Rev Respir Dis 1987;136:1285–98.
9. American Thoracic Society. Guidelines for methacholine and
exercise challenge testing. Am J Respir Crit Care Med
1999;161:309–29.
ARTICLE IN PRESS
Diagnostic utility of inflammatory biomarkers in asthma 242110. American Thoracic Society. Recommendations for standardised
procedures for the online and offline measurement of exhaled
lower respiratory nitric oxide and nasal nitric oxide in adults
and children. Am J Respir Crit Care Med 1999;160:2104–17.
11. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide
measurements: recommendations. European Respiratory So-
ciety Task Force. Eur Respir J 1997;10:1683–93.
12. Calaf N, De Lerma JB, Feixas T, Gonzalez M, Codina E, Casan P,
et al. Exhaled nitric oxide: reference values in healthy adults.
Arch Bronconeumol 2004;40(Suppl. 2):66.
13. Efthimiadis A, Pizzichini E, Pizzichini M, Hargreave FE. Sputum
examination for indices of airway inflammation: laboratory
procedures. Canadian Socie´te´. Lund, Sweden: Thoracic Society
Canadienne de Thoracologie, Astra Draco AB; 1997.
14. Belda J, Leigh R, Parameswaran K, O0Byrne PM, Sears MR,
Hargreave FE. Induced sputum cell counts in healthy adults. Am
J Respir Crit Care Med 2000;161:475–8.15. Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefler SJ.
The aerocrine exhaled nitric oxide monitoring system NIOX is
cleared by de US Food and Drug Administration for monitoring
therapy is asthma. J Allergy Clin Immunol 2004;114(5):
1241–56.
16. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflamma-
tion in asthma. N Engl J Med 1990;323(15):1033–9.
17. Delen FM, Sippel JM, Osborne ML, Law S, Thukkani N, Holden
WE. Increased exhaled nitric oxide in chronic bronchitis:
comparison asthma and COPD. Chest 2000;117:695–701.
18. Kharitonov SA, Wells AU, O0Connor BJ, et al. Elevated levels of
exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care
Med 1995;151:1889–93.
19. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP. Increased level
of exhaled nitric oxide and up-regulation of inducible nitric
oxide synthase in patients with primary lung cancer. Br J Cancer
1998;78:534–41.
